{
    "clinical_study": {
        "@rank": "36705", 
        "arm_group": [
            {
                "arm_group_label": "Moxifloxacin 400mg", 
                "arm_group_type": "Experimental", 
                "description": "moxifloxacin 400mg"
            }, 
            {
                "arm_group_label": "Moxifloxacin 800mg", 
                "arm_group_type": "Experimental", 
                "description": "moxifloxacin 800mg"
            }, 
            {
                "arm_group_label": "Placebo(No treatment)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate effect of moxifloxacin on QT/QTc interval in\n      healthy male subjects. Moxifloxacin is a positive control drug used in QT study. In this\n      study, moxifloxacin 400mg and 800mg will be used, to get information on effect of\n      moxifloxacin on QT/QTc interval."
        }, 
        "brief_title": "A Study Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "the Effect of Moxifloxacin on QT/QTc Interval", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy male subject aged 20 to 40 at screening\n\n          -  subjects who have weight over 50 kg with ideal body weight range of +- 20%\n\n          -  subjects who decide to participate voluntarily and write a informed consent form\n\n        Exclusion Criteria:\n\n          -  subjects who have acute illness within 28 days of investigational drug administration\n\n          -  subjects who have clinically significant disease of cardiovascular, respiratory,\n             renal, endocrinological, hematological, gastrointestinal, neurological(central\n             nervous system), psychiatric disorders or malignant tumor\n\n          -  subjects who have determined not eligible by screening test (medical history,\n             physical examination, 12-lead ECG, laboratory test, etc) within 28 days of study\n             start\n\n          -  clinically significant allergic disease (except for mild allergic rhinitis)\n\n          -  systolic blood pressure>= 140 mmHg, diastolic blood pressure >= 90 mmHg, heart rate >\n             100 bpm or < 50 bpm\n\n          -  result of 12-lead electrocardiogram includes :\n\n               -  QTcF > 450 msec\n\n               -  PR interval > 200 msec or <110msec\n\n               -  Evidence of second- or third-degree atrioventricular (AV) block\n\n               -  Pathologic Q waves (defined as Q-wave > 40 msec or depth > 0.5 millivolt\n\n               -  Evidence of ventricular pre-excitation, left bundle branch block (LBBB), right\n                  bundle branch block (RBBB)\n\n               -  Intraventricular conduction delay with QRS > 120 msec\n\n          -  risk of Torsade de pointes such as long QT syndrome, family history of  sudden death,\n             heart failure, hypokalemia\n\n          -  Subjects considered unsuitable for inclusion by the investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756521", 
            "org_study_id": "MOXI036"
        }, 
        "intervention": {
            "arm_group_label": [
                "Moxifloxacin 400mg", 
                "Moxifloxacin 800mg"
            ], 
            "intervention_name": "Moxifloxacin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "QT,", 
            "QTc,", 
            "electrocardiogram,", 
            "moxifloxacin"
        ], 
        "lastchanged_date": "December 4, 2013", 
        "link": {
            "description": "webpage of clinical trial center of Seoul National University Hospital", 
            "url": "http://ctc.snuh.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multi-center, Randomized, Open-label, Placebo-controlled, 3-way Crossover Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "QTc (QTcF, QTcB, QTcI)\nQTcF (Fridericia-corrected QTc)\nQTcB (Bazett-corrected QTc)\nQTcI (Individual-corrected QTc)\nQTc change: the largest time-matched, baseline-adjusted least squares mean difference time-matched, baseline-adjusted least squares mean difference", 
            "measure": "QTc (QTcF, QTcB, QTcI)", 
            "safety_issue": "Yes", 
            "time_frame": "Day1 and Day2 of each periods(3 periods)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756521"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Kyung-Sang Yu", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Korea National Enterprise for Clinical Trials", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Catholic University of Korea", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Seoul National University Bundang Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}